Alpha 2.0
Login Register
» Articles » PMID: 6107263

Effect of Sulphapyridine, 5-aminosalicylic Acid, and Placebo in Patients with Idiopathic Proctitis: a Study to Determine the Active Therapeutic Moiety of Sulphasalazine

Overview
Journal Gut
Specialty Gastroenterology
Date 1980 Jul 1
PMID 6107263
Citations 98
Authors
P A van Hees
J H BAKKER
J H van Tongeren
Affiliations
Soon will be listed here.
Abstract

Suppositories of sulphapyridine, 5-aminosalicylic acid, and placebo were used in 45 patients with idiopathic proctitis to determine the active part of sulphasalazine. Each patient used one of the suppositories twice daily for four weeks in a double-blind controlled trial. Complete clinical remission with normal rectal mucosa on sigmoidoscopy occurred in 60% of patients given 5-aminosalicylic acid, but in only 13% and 27% of those given sulphapyridine and placebo respectively. Twelve patients were included twice. In eight of these patients 5-aminosalicylic acid was given one time and sulphapyridine (two patients) or placebo (six patients) another time. Clinical remission occurred in each patient with 5-aminosalicylic acid, but in only one patient during other therapy. The results suggest that 5-aminosalicylic acid is the active therapeutic moiety of sulphasalazine.

Citing Articles

Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.

Aruljothy A, Singh S, Narula N, Moran G, Vuyyuru S, Hogan M Aliment Pharmacol Ther. 2023; 58(8):740-762.

PMID: 37589498 PMC: 11162959. DOI: 10.1111/apt.17666.

Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.

Murray A, Nguyen T, Parker C, Feagan B, MacDonald J Cochrane Database Syst Rev. 2020; 8:CD000544.

PMID: 32856298 PMC: 8094989. DOI: 10.1002/14651858.CD000544.pub5.

Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.

Murray A, Nguyen T, Parker C, Feagan B, MacDonald J Cochrane Database Syst Rev. 2020; 8:CD000543.

PMID: 32786164 PMC: 8189994. DOI: 10.1002/14651858.CD000543.pub5.

Assessment of contribution of BCRP to intestinal absorption of various drugs using portal-systemic blood concentration difference model in mice.

Kawahara I, Nishikawa S, Yamamoto A, Kono Y, Fujita T Pharmacol Res Perspect. 2020; 8(1):e00544.

PMID: 31988753 PMC: 6968775. DOI: 10.1002/prp2.544.

Conjugation of Amisulpride, an Anti-Psychotic Agent, with 5-Aminosalicylic Acid via an Azo Bond Yields an Orally Active Mutual Prodrug against Rat Colitis.

Kim W, Kim D, Jeong S, Ju S, Lee H, Kim S Pharmaceutics. 2019; 11(11).

PMID: 31703411 PMC: 6920822. DOI: 10.3390/pharmaceutics11110585.

References
1.
Hansson K, Sandberg M . Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine. Acta Pharm Suec. 1973; 10(1):87-92. View
2.
Baron J, Connell A, Lennard-Jones J, JONES F . Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet. 1962; 1(7239):1094-6. DOI: 10.1016/s0140-6736(62)92080-9. View
3.
Peppercorn M, Goldman P . Distribution studies of salicylazosulfapyridine and its metabolites. Gastroenterology. 1973; 64(2):240-5. View
4.
van Hees P, Tuinte J, van Rossum J, van Tongeren J . Influence of intestinal transit time on azo-reduction of salicylazosulphapyridine (Salazopyrin). Gut. 1979; 20(4):300-4. PMC: 1412401. DOI: 10.1136/gut.20.4.300. View
5.
FOLLEY J . Current concepts: ulcerative proctitis. N Engl J Med. 1970; 282(24):1362-4. DOI: 10.1056/NEJM197006112822407. View